ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

ClinicalTrials.gov ID: NCT03226678

Public ClinicalTrials.gov record NCT03226678. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Study identification

NCT ID
NCT03226678
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Enrollment
24 participants

Conditions and interventions

Interventions

  • APL-2 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 30, 2017
Primary completion
Sep 11, 2022
Completion
Sep 11, 2022
Last update posted
Dec 11, 2024

2017 – 2022

United States locations

U.S. sites
8
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
American Institute of Research Whittier California 90603
Lakes Research Miami Lakes Florida 33014
Mid Florida Hematology Oncology Orange City Florida 32763
University of Iowa Hospitals Iowa City Iowa 52242
Mayo Clinic Rochester Minnesota 55905
East Carolina University Greenville North Carolina 27834
University of Tennessee Medical Center Knoxville Tennessee 37920
Northwest Medical Specialties Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03226678, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 11, 2024 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03226678 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →